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Activation of human and rabbit prokallikrein by serine and metal-
loproteases. Human and rabbit kidney and urine contain an inactive
form of kallikrein. Studies on the mRNA sequence suggested that the
active form of the enzyme and the propeptide are linked by a peptide
bond between a basic and hydrophobic amino acid. We studied the
activation of prokallikrein by serine proteases and a neutral metal-
loproteinase, thermolysin. because serine proteases cleave the peptide
chain after a basic amino acid and thermolysin before a hydrophobic
amino acid. The activity of kallikrein was measured by RIA and with a
fluorogenic peptide substrate. Trypsin was used as a standard reference
activator. We found that human plasmin and plasminogen, activated by
urokinase, activate prokallikrein. Pronase coupled to Sepharose also
enhanced the activity of the renal kallikrein zymogen. On a molar basis,
thermolysin was a more ell'ective activator of prokallikrein than trypsin.
The activation by thermolysin was blocked by the inhibitor
phosphoramidon, but not by DFP or SBTI. These experiments indicate
that, in addition to serine proteases, neutral metalloproteases of tissues
may activate prokallikrein.
Activation de La prokallicreine d'homme et de lapin par les sérine et
metalloprotéases. Le rein et les urines d'homme et de lapin contiennent
une forme inactive de kallicréine. Des etudes de Ia sequence du mRNA
ont suggéré que la forme active de l'enzyme et le propeptide sont reliCs
par une liaison peptidique entre des acides aminCs basique et
hydrophobe. Nous avons Ctudié l'activation de La prokallicreine par des
sérine protCases et par une métallo protCinase neutre, Ia thermolysine,
car les sérine protCases clivent Ia chaine peptidique après un acide
amine basique. et Ia thermolysine avant un acide amine hydrophobe.
L'activitC de Ia kallicrCine a etC mesurCe par RIA et avec un substrat
peptidique fluorogene. La trypsine a etC utilisCe comme standard
activateur de rCférence. Nous avons trouvC que Ia plasmine et Ic
plasminogCne humains, activés par l'urokinase, activent Ia
prokallicrCine. La pronase couplCe au Sepharose a egalement stimulé
l'activitC du zymogène renal, Ia kallicrCine. Sur one base molaire, Ia
thermolysine Ctait on activateur plus efficace de Ia prokallicreine que la
trypsine. L'activation par Ia thermolysine était bloquée par Ic
phosphoramidon, on inhibiteur. mais non par le DFP ou Ic SBTI. Ces
experiences indiquent qu'en plus des sérine protCases, les mélallo-
protCases neutres tissulaires peuvent activer Ia prokallicréine.
Biologically active factors in urine have been investigated for
a century [1—3], but many aspects of the biosynthesis and
function of the hypotensive enzyme kallikrein are yet to be
unraveled. Prokallikrcin is excreted in urine [4—61 and is present
in the kidney [7—131, but the ratio of active kallikrein to the
proenzyme can differ from one species to another. Rat urine
mostly contains active kallikrein [141, while membrane frag-
ments such as the basolateral membrane-enriched fraction
isolated from the rat kidney mainly contain the proenzyme [10,
11, 141.
We first studied prokallikrein in the rat kidney and showed
that both trypsin and plasmin activate it [7—101, and that
dexamethasone increases its excretion in rat urine [14]. To learn
more about the mode of activation of prokallikrein, we inves-
tigated this enzymatic process in human and rabbit urine and
kidney, which contain more prokallikrein than rat urine [5, 6,
12—14]. Roughly one-half to two-thirds of the kallikrein in rabbit
kidney or human urine is present in inactive form [5, 6, 12, 131.
In this study, we used renal membrane-enriched fractions and
urinary ultrafiltrates as sources of prokallikrein. In addition to
trypsin and plasmin which cleave peptide bonds of basic amino
acids such as arginine, we investigated the activation of prokal-
likrein by thermolysin that hydrolyzes peptides at the N-
terminal end of hydrophobic amino acids. Presumably, human
and rabbit prokallikrein are activated by cleavage of a peptide
bond between a basic and hydrophobic amino acid. We found
that in addition to serine proteases, thermolysin, a neutral
metalloproteinase (E.C 3.4.24.4), is an effective activator of
prokallikrein.
Methods
D - Val -Leu -Arg-4- trifluoromethylcoumarin -7- amide (AFC
substrate) was purchased from Enzyme Systems Products,
Livermore, California, USA; trypsin from Worthington Bio-
chemical Corporation, Freehold, New Jersey, USA; benzoyl-
Arg-naphthylamide and soybean trypsin inhibitor from Sigma
Chemical Co., St. Louis, Missouri, USA; CNBr-activated
Sepharose 4B from Pharmacia Fine Chemicals, Piscataway,
New Jersey, USA; pronase and thermolysin from Calbiochem-
Behring Corporation, La Jolla, California, USA; human
plasmin and plasminogen from Kabi Dignostica, Stockholm,
Sweden; urokinase from The Green Cross Corporation, Osaka,
Japan. Phosphoramidon was a gift from Dr. R. Mumford of
Merck Research Institute, Rahway, New Jersey, USA; and
antiserum to bradykinin was donated by Dr. 0. A. Carretero,
Henry Ford Hospital, Detroit, Michigan, USA.
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Fractionation of kidneys
New Zealand white rabbits were killed by decapitation after
intravenous injection of 1,000 U of heparin. The kidneys were
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perfused with isotonic saline until all visible blood was re-
moved. All subsequent steps were performed at 4°C. Renal
cortices, dissected from the kidneys of two to three rabbits,
were pooled, minced, and homogenized with a homogenizer
(Teflon®) in ten volumes of 10 mrvi Tris-HC1, pH 7.4 containing
0.25 M sucrose. Blood-free human cadaver kidneys, which were
discarded because they could not be used for transplantation,
were obtained with permission of the Human Experimentation
Committee from Parkland Memorial Hospital. Kidney cortex
was dissected, minced, and homogenized in a blender
(Waring®) for 30 sec and then with a homogenizer (Teflon®) in
the above buffer. The details of the separation of the membrane
fragments were described elsewhere [8]. Briefly, the homogen-
ate was centrifuged for 30 mm at x 30,000g, and the resulting
supernatant was centrifuged for 45 mm at x 100,000g. The
pellet containing microsomal particles (P1) was washed
hypotonically by resuspending it in 10 m Tris-HCI, pH 8.6,
and centrifuging for 45 mm at x 100,000g. The washing proce-
dure was repeated once with 10 mri Tris-HC1, pH 8.6, and once
with 1 msi Tris-HC1, pH 8.6. The final pellet (P2) was used in the
experiments. For measuring enzymatic activity in the washed
microsomal (P2) fraction, the membrane-bound enzyme and
proenzyme were solubilized with 0.1% Triton X-lOO in 10 mM
Tris-HC1 buffer, pH 7.4, for 30 mm at 4°C, then centrifuged for
60 mm at x 100,000g. The supernatant was then assayed for the
activity.
Collection of urine
Rabbit urine specimens were collected through a stainless
steel funnel into plastic cups while rabbits were kept in stainless
steel cages. Human urine was pooled after collection from three
or more individuals. The urine was centrifuged at x 3,000g for
15 mm and concentrated about tenfold in an ultrafiltration
apparatus with a YM-lO membrane (Amicon). Concentrated
urine was stored at —20°C until assayed.
Enzyme assays
Kallikrein activity was determined fluorometrically [15] with
D-Val-Leu-Arg-AFC substrate. Although we previously used
the chromogenic substrate, D-Val-Leu-Arg-p-nitroanilide
(S2266) [14], we chose the fluorometric method this time
because it is faster and more sensitive than the chromogenic
substrate assay.
Fifty microliters of urine or membrane preparation were
mixed with 445 pi of 0.1 M Tris-HCI buffer, pH 8.0. The
reaction was initiated with 5 l of 10 mrvi AFC substrate
dissolved in dimethylsulfoxide. After incubation at 37°C, the
reaction was stopped by adding 5 l of 50% acetic acid. The
amount of fluorogenic coumarin derivative liberated was mea-
sured in a spectrophotofluorometer (Aminco-Bowman) with
excitation at 400 and emission at 505 nm. Alternatively, the
reaction was carried out in the cuvette and the increase in
fluorescence monitored directly with a recorder. Kallikrein
activity was also assayed by measuring the release of bradyki-
nm from heated dog plasma (the source of kininogen substrate)
in a radioimmunoassay (RIA) [8]. The kallikrein activity is
expressed as nanograms of bradykinin equivalent released.
As we reported, chromogenic substrate (S2266) hydrolysis
correlates well with the bioassay of urinary kallikrein [141.
Here, we also found good correlation of kallikrein activity
measured with AFC substrate or S2266 and RIA measurement
as shown by linear regression analysis; (AFC vs. RIA, r =0.83,
N = 48, P < 0.001; S2266 vs. RIA, r = 0.82, N = 48,P < 0.001).
Trypsin
Trypsin was used as a reference activator in routine experi-
ments. An aliquot of the solubilized membrane fraction or urine
sample was treated with 5 g of trypsin in 0.1 M Tris-HCI
buffer, pH 7.4, for 30 mm at 37°C, The reaction was stopped
with 25 g of soybean trypsin inhibitor (SBTI). Control experi-
ments showed that this amount of SBTI completely inhibited
trypsin activity.
Pronase
Sepharose 4B-bound pronase was prepared by coupling 27
mg of pronase with 5 ml of CNBr-activated Sepharose 4B
according to the manufacturer's instructions. The activities of
soluble pronase and Sepharose-pronase were measured using
benzoyl-Arg-naphthylamide as substrate. An aliquot of the
Sepharose-pronase suspension, containing an equivalent activ-
ity ranging from 1.8 to 36 tg of soluble pronase, was diluted to
200 l in 0.1 M Tris-HCI, pH 7.4, and added to 100 1d of
solubilized human or rabbit P2 fraction. The mixture was
incubated at room temperature (25°C) for 60 mm in tubes
rotated on a turntable. The reaction was stopped by sediment-
ing the Sepharose-pronase at x2500g for 3 mm. The super-
natant was used for kallikrein assays and protein determina-
tions.
Plasmin and activated plasminogen
The equivalent of 2 Casein Units (CU) of plasminogen (200
d) was activated by added urokinase (200 l, 600 IU) for 2 hr
at room temperature. The solubilized human and rabbit P2
fractions were incubated with various amounts of human
plasmin (31.3 to 500 mCU) or with activated plasminogen (6.25
to 50 mCU). After incubation for 30 mm at 37°C, plasmin was
inactivated by adding 25 tg of SBTI and the kallikrein activity
was measured.
Thermolysin
The P2 fractions (50 jd) or urine samples (50 ILl) were
preincubated for 30 mm at 37°C with varying concentrations of
thermolysin or, as a control, with trypsin (ranging from 0.125 to
10 g/ml) in 495 IL1 of 0.1 M Tris-HC1 buffer, pH 8.0, containing
10 m'i CaCl2. After adding 5 1d of phosphoramidon (to a final
concentration of 10 ILM) or 5 IL1 of SBTI (10 mg/ml), an aliquot
(50 to 250 iil) was taken and assayed for kallikrein activity by
both fluorometry and RIA. In control studies, thermolysin and
trypsin activity were inhibited by phosphoramidon and SBTI,
respectively, prior to adding prokallikrein. When thermolysin
was treated with 1 mi DFP (diisopropylfluorophosphate) for 60
mm, it was subsequently dialyzed against the assay buffer to
remove traces of unreacted DFP.
All experiments were done in duplicate or triplicate, and the
results are given as the mean value or mean SE for studies
performed with membrane preparations from rabbit and human
kidneys and with urine samples.
Protein determinations
Protein concentration was measured according to Lowry et al
[16] using bovine serum albumin as the standard.
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Fig. 1. Activation of renal prokallikrein in P2 fractions by Sepharose-
pronase. The ordinate represents the percent increase in kininogenase
activity in human (S—•) and in rabbit (A—A) kidney membrane
fractions; the abscissa represents Sepharose-pronase activity ex-
pressed in soluble pronase equivalents, jsg.
Results
Renal prokallikrein
Trypsin was used routinely as an activator to establish the
maximum activation of prokallikrein in the rabbit and human
kidney and in urine.
The concentration of active kallikrein in the P2 fraction of
human kidney was very low. Under standard conditions, tryp-
sin (5 /Lg) activated prokallikrein and increased the activity from
0.23 0.32 (SE) to 2.25 0.36 nmoles/min/mg, respectively,
when assayed fluorometrically and from 0.87 0.19 to 2.50
0.37 ng/min/mg, respectively, in the kininogenase assay. The
activity detected in the human P1 fraction with either the
fluorimetric assay or RIA was lower. The corresponding num-
bers are 0.12 0.03 and 0.15 0.04 before the activation and
1.13 0.46 and 1.1 0.4, respectively, after trypsin activation.
The rabbit kidney P2 fraction contains both prokallikrein and
kallikrein in higher concentration than human kidney. Kal-
likrein activity was 1.86 0.21 nmoles/min/mg in the P2 fraction
and increased to 8.8 0.7 after trypsin treatment in the
fluorometric assay. With the kininogenase RIA assay, the
corresponding numbers in the rabbit kidney fractions were 9.7
0.5 ng/min/mg for active kallikrein, and 36 2 after
activation.
Pronase
Figure 1 shows the percent activation of prokallikrein in
rabbit and human kidney P2 fraction by Sepharose-bound
pronase. In the rabbit, Sepharose-pronase with an equivalent
activity of 3.6 g of free pronase activated prokallikrein maxi-
mally. Kininogenase activity, as determined by RIA, increased
about threefold after the Sepharose-pronase treatment in the P2
fraction. A similar kallikrein activation pattern was seen in the
human kidney P, fraction after treatment with Sepharose-
pronase, except here the activity increased about sixfold. In
absolute terms, the human P2 fraction was much less active than
the rabbit as stated above. The amount of kinin liberated by the
P2 fraction after pronase treatment was about the same as found
after activation with tryp sin. The specific activity of the human
P2 fraction after pronase activation in bradykinin equivalents
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Fig. 2. Activation of renal prokallikrein in P2 fractions by human
plasmin. The ordinate represents the percent increase in kininogenase
activity in human (•—•) and in rabbit (A—A) kidney membrane
fractions; the abscissa represents plasmin in casein units (CU) x l0.
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Fig. 3. Activation of human renal prokallikrein in the P2 fraction by
plasminogen preactivated by urokinase. The ordinate represents brady-
kinin equivalents released; the abscissa represents plasminogen in
plasmin equivalent casein units x l0—.
was 1.4 ng/min/mg and that in the rabbit fraction was 40
ng/min/mg.
Human plasmin
Figure 2 shows the percent activation of kininogenase activ-
ity in rabbit and human kidney P2 fraction as a function of
human plasmin concentration. The activation reached a maxi-
mum at 250 mCU of plasmin with human kidney and was
equivalent to the activation seen with 5 jtg trypsin. Human
plasmin was less effective in activating rabbit kidney prokal-
likrein when compared to human prokallikrein.
Human plasminogen
Figure 3 shows that plasminogen, after activation with
urokinase, in turn activated prokallikrein in the P2 fraction of
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Fig. 4. Activation of renal prokallikrein in P2 fractions by thermolysin
(•—•) and trypsin (A—A). The upper panel shows the rabbit P2
fraction; the lower panel, human P2 fraction; inhibited reactions, 10 ILM
phosphoramidon (O---O) and 50 jzglml SBTI (A---A). The ordinate
represents kininogenase activity in bradykinin equivalents, the ab-
scissa, micrograms of enzyme per milliliter of incubation mixture.
human kidney. Renal prokallikrein in the rabbit and human
kidney was not activated by urokinase or by plasminogen alone
(not shown).
The rmolysin
In addition to serine proteases, such as trypsin or plasmin,
prokallikrein was activated by thermolysin, an enzyme with an
entirely different substrate specificity. Figure 4 shows the effect
of increasing concentrations of thermolysin on prokallikrein
activation in the rabbit and human kidney P2 fraction. The
activation, which was maximal at about 2 g/ml thermolysin (37
nM), was completely inhibited by the specific inhibitor,
phosphoramidon (10 LM), at the lower enzyme concentrations.
Phosphoramidon (10 M) inhibited the kininogenase activation
80 to 94% at the higher concentration of thermolysin.
The activation of prokallikrein by thermolysin was also
inhibited 90 to 95% by o-phenanthroline (1 mM), EDTA (3 mM),
dithiothreitol (0.1 mM), and 2,3-dimercapto-l-propanol (0.1
mM), but not by DFP (1 mM) (not shown). These compounds
very likely inhibited thermolysin by binding its metal cofactor,
zinc. At the concentrations used, the inhibitors either did not
affect kallikrein activity or the unreacted inhibitor was removed
by dialysis (DFP).
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Fig. 5. Activation of human urinary prokallikrein by thermolysin (S—
•) and trypsin (A—A). Ordinate.' kallikrein activity expressed as
nanomoles of AFC liberated per minute per milliliter of urine. The
abscissa represents the concentration of added enzyme in micrograms
per milliliters of incubation mixture. Inhibited reaction is 10 /.LM
phosphoramidon (O---O) SBTI, 50 tg/ml (A---t).
Figure 4 also compares the activation by trypsin and
thermolysin under identical assay conditions. Because of dif-
ferences in molecular weight and additives in the commercial
enzyme preparations used, when the concentrations bf the two
enzymes were equivalent by weight, the molar concentration of
thermolysin was half of that of trypsin. The activation by
trypsin was completely inhibited by SBTI.
Urinary prokal/ikrein
Human urinary prokallikrein was activated by both trypsin
and thermolysin. Trypsin was effective at a lower concentration
with the urinary than with the renal membrane proenzyme. This
was established by fluorometric assay (Figs. 5 and 6) and by
RIA. Maximum activation was obtained at about 1 g/ml
concentrations of the enzymes, which is equivalent to 43 nM
trypsin or 19 nM thermolysin. This amount of trypsin increased
the kallikrein activity in urine from 4.4 to 12.3 nmoles
AFC/min/ml whereas the thermolysin-treated sample yielded
11.5 nmoles/min/ml. Phosphoramidon (10 /SM) completely in-
hibited the activity of thermolysin at lower concentrations of
the enzyme.
Figure 6 shows the tracing of an experimental recording of
human urinary prokallikrein activation by thermolysin. The
figure also shows that pretreatment with DFP had no effect on
the activity of thermolysin, while phosphoramidon inhibited it.
The kininogenase activity of urinary prokallikrein increased
from 9.2 to 21.2 ng/min/ml after thermolysin treatment (1 tg/ml)
and to 22.8 after 1 gIml trypsin was added. Phosphoramidon
inhibited thermolysin to the same extent as in the fluorometric
assay. However, the percent activation of urinary prokallikrein
was lower than that of renal kallikrein because a larger portion
of the kallikrein was in an active form in the urine than in the P2
fraction.
Rabbit urinary prokallikrein was also activated by tryp sin and
thermolysin. In these fluorometric experiments trypsin or
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Fig. 6. Direct recording of initial rates of activation of urinary prokal-
likrein in a spectrophotofluorometer. The substrate used was D-Val-
Leu-Arg-AFC. DFP did not but phosphoramidon did inhibit the activa-
tion by thermolysin. The numbers represent (1) urinary prokallikrein
activated by thermolysin; (2) same as (I) hut thermolysin was pre-
treated with DFP; (3 and 4) same as (1) and (2), but 10 zMphos-
phoramidan was added; (5) control, no thermolysin used.
thermolysin (5 g/ml) increased the activity in rabbit urine from
4.8 nmoles/min/ml to 16.5 and 11, respectively.
Discussion
These experiments showed that, in addition to serine
proteases, thermolysin, a proteolytic enzyme of a different
specificity, activates prokallikrein.
How kallikrein activity can be so high in urine [17] while it is
quite low in kidney has been a puzzle for a long time. Rapid
biosynthesis and turnover in renal tissues may partly be respon-
sible for this discrepancy [18]. Renal kallikrein is membrane-
bound [19—21], mostly in the form of an inactive proenzyme
[7—11, 22] and has to be solubilized first, then activated to
estimate the total kallikrein activity in this tissue [7, 8, 10, 111.
This could also account, in part, for the low kallikrein activity
found in kidney homogenates. In addition, urine contains an
inactive, pro-form of kallikrein [3, 41 which can amount to more
than half of the total urinary kallikrein activity in human
subjects [5, 61.
Kallikrein in the kidney is present in the distal tubules on the
luminal surface [12, 13, 23—27] and also on the basolateral
membrane [10, 11, 28, 29]. This dual localization makes it
possible for renal kallikrein to be released both into the circula-
tion of the perfused kidney [30—34] and into the urine.
80 The activation of prokallikrein is a multi-step procedure.
First, it has to be solubilized from the membrane as we have
seen in the rat kidney [7, 8], and subsequently activated very
likely by the cleavage of an N-terminal peptide. We know from
studies on the nucleotide sequence of rat kallikrein mRNA that
an Arg-Val bond has to be cleaved to release an undecapeptide
when pancreatic prokallikrein is activated [35]. Such a bond
should be susceptible to hydrolysis by trypsin and plasmin. In
the present study, it was shown that human plasminogen was
50 also an activator of prokallikrein, provided it is activated first
by urokinase. The major finding in this report, however, is that
thermolysin, a neutral metalloprotease which hydrolyzes pep-
40 tide bonds at the amino terminal side of hydrophobic amino
• acids [36], also activates human and rabbit prokallikrein. Pre-
sumably, this is due to the cleavage of a bond similar to
Arg-Val, such as Arg-Ile, to remove the N-terminal peptide30 from (prokallikrein) kallikrein. Indeed, thermolysin [36], and a
human neutral metalloendopeptidase as well, can cleave pep-
tide bonds adjacent to hydrophobic amino acids (for example,
Val, Phe) as in angiotensin I and II [37]. The kidney is rich in
this metalloendopeptidase [37, 381, also referred to as
"enkephalinase" because one of its substrates is enkephalin.
Thermolysin, a commercially purified bacterial enzyme, has a
similar substrate specificity [36], hence, we used it in these
experiments.
Pronase, another bacterial enzyme, probably acts similarly to
trypsin [39]. In addition to activation, it may also partially
solubilize the membrane-bound prokallikrein.
Trypsin was more effective in activating prokallikrein in the
P2 than in the P1 fraction. The difference in the preparation of
the two fractions (P2 and P1) consists of the osmotic shock
induced by hypotonic washing. The washing, in addition to
removing any soluble kallikrein trapped in the P1 fraction, also
possibly removed a trypsin inhibitor. Indeed, the urinary
proenzyme was activated by lower concentrations of trypsin
and thermolysin than the renal enzyme.
In some experiments with trypsin, the hydrolysis of the AFC
substrate was activated more than the kininogenase activity.
This was taken as an indication that the tissues may contain
another prokallikrein-type enzyme which cleaves D-Val-Leu-
Arg-AFC, but does not release kinin from dog plasma
kininogen. Because this did not happen with thermolysin, this
enzyme may be a more specific activator of prokallikrein than
trypsin.
Thermolysin was inhibited by phosphoramidon, an inhibitor
of thermolysin [40] and the mammalian neutral endopeptidase
[371, and by metal binding agents, but not by DFP. Although 10
/LM is a higher concentration of phosphoramidon than used
previously, the degree of inhibition depended on the concentra-
tion of the enzyme as the inhibitor had to be present in excess
for a more than 80% inhibition. In addition, the inhibition of the
cleavage of such a large substrate as prokallikrein (the molecu-
lar weight estimated to be about 35 to 40,000 in rabbits) may
require higher concentrations of inhibitor than with the short
peptide substrates.
In conclusion, renal kallikrein, an enzyme considered by
many to have important functions in the kidney and in the
circulation [17, 41—43] is activated from its proenzyme form by
both serine proteases and by the neutral metalloprotease
thermoly sin.
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